Close Menu

MALDI mass spectrometry

Scientists from the University of Victoria, SISCAPA Assay Technologies, and Bruker have demonstrated the use of MALDI mass spectrometry for quantifying levels of the putative prostate cancer marker protein C inhibitor in clinical samples.

NEW YORK (GenomeWeb News) – Bruker said today that it has entered an agreement with Loos, France-based biotech firm ImaBiotech to distribute that company's Quantinetix software for MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – CovalX and Bruker's Daltonics division today announced an agreement to combine their technologies to support research into protein interactions and macromolecular characterization.

NEW YORK (GenomeWeb News) – Bruker said today it has signed an exclusive patent license agreement with 3M Company that allows it to include in its products patented 3M technology related to MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – Bruker said today it has entered an exclusive partnership with German software firm Scils for informatics tools supporting MALDI mass spec imaging.

NEW YORK (GenomeWeb News) – BD Diagnostics and Bruker are updating a 2010 agreement to include international distribution of the co-labeled BD Bruker Maldi Biotyper system.

Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said this week that they are collaborating on high-throughput iMALDI mass spec-based assays for determining genetic hemoglobin variants and diabetes risk.

NEW YORK (GenomeWeb News) – Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said today that they are collaborating on developing high-throughput iMALDI mass spectrometry-based assays for determining genetic hemoglobin variants and diabetes risk.

NEW YORK (GenomeWeb News) – Glycomics firm Ezose Sciences said today it has fully aligned its business with Shionogi's Diagnostics Division following its acquisition by the Japanese pharmaceutical firm.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.